Board Member
Starling Oncology, Inc. (STLN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Daniel Virnich is recorded as Board Member, CEO and COO at Starling Oncology, Inc. (STLN). Starling Oncology, Inc. reported in an 8-K filed June 12, 2023 that Daniel Virnich was appointed Chief Executive Officer, effective June 30, 2023. The proxy statement of Starling Oncology, Inc. reports total compensation of $1,934,930 for Daniel Virnich in fiscal 2025, including a base salary of $475,000. Disclosed compensation is on record for 6 fiscal years. Daniel Virnich has spoken on 6 earnings calls across 1 company, most recently for Starling Oncology, Inc. on March 12, 2026.
“Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company's current President, as Chief Executive Officer, and in such role he will serve as the Company's principal executive officer pursuant to his existing employment agreement with the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2021-11-12–present
Start not stated–present
Start not stated–present
Proxy statement
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Recorded roles and call appearances connecting this person to public companies.
Board Member, CEO, COO
2021-11-12–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Starling Oncology, Inc. (STLN) | — | $475,000 | $1,934,930 |
| 2024 | Starling Oncology, Inc. (STLN) | — | $475,000 | $1,118,358 |
| 2023 | Starling Oncology, Inc. (STLN) | — | $455,000 | $808,129 |
| 2022 | Starling Oncology, Inc. (STLN) | — | $446,458 | $3,244,461 |
| 2021 | Starling Oncology, Inc. (STLN) | — | $262,500 | $7,638,167 |
| 2020 | Starling Oncology, Inc. (STLN) | — | $213,542 | $418,684 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
